{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:26:32Z","timestamp":1787372792021,"version":"build-2736575974"},"reference-count":36,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.6875-25","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:10:47Z","timestamp":1787091047000},"source":"Crossref","is-referenced-by-count":0,"title":["Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Japanese Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: A Phase 3, Open-label Clinical Trial"],"prefix":"10.2169","author":[{"given":"Satoshi","family":"Kuwabara","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tomizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Fujita Health University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kuga","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Li","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay","family":"Hakan","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"},{"name":"Department of Neurology and Neurological Science, Institute of Science Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the HyQvia Japan CIDP\/MMN Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. K\u00f6ller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352: 1343-1356, 2005.","DOI":"10.1056\/NEJMra041347"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86: 973-985, 2015.","DOI":"10.1136\/jnnp-2014-309697"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology 52: 161-172, 2019.","DOI":"10.1159\/000494291"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Aotsuka Y, Misawa S, Suichi T, et al. Prevalence, clinical profiles, and prognosis of CIDP in Japanese nationwide survey: analyses of 1,257 diagnosis-confirmed patients. Neurology 102: e209130, 2024.","DOI":"10.1212\/WNL.0000000000209130"},{"key":"5","unstructured":"5. Committee of Japanese Society of Neurology. Chronic inflammatory demyelinating polyradiculoneuropathy\/multifocal motor neuropathy, overview. In: Practical Guidelines of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy. Creating Committee of Practical Guidelines of Chronic Inflammatory Demyelinating Polyradiculoneuropahy and Multifocal Motior Neuropathy, Ed. Nankodo, Tokyo, Japan, 2024 (in Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst 26: 242-268, 2021.","DOI":"10.1111\/jns.12455"},{"key":"7","unstructured":"7. argenx. argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy [Internet]. [cited 2026 Jan 16]. Available from: https:\/\/argenx.com\/news\/2024\/argenx-announces-approval-of-vyvdura--efgartigimod-alfa-and-hyal"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 15: 295-301, 2010.","DOI":"10.1111\/j.1529-8027.2010.00290.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lawson VH, Arnold WD. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat 10: 567-576, 2014.","DOI":"10.2147\/NDT.S39592"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Aotsuka Y, Misawa S, Suichi T, et al. Multifocal motor neuropathy in Japan: a nationwide survey on prevalence, clinical profiles, and treatment. Muscle Nerve 70: 1027-1033, 2024.","DOI":"10.1002\/mus.28251"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Claytor B, Polston D, Li Y. Multifocal motor neuropathy: a narrative review. Muscle Nerve 71: 512-534, 2025.","DOI":"10.1002\/mus.28349"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc 93: 777-793, 2018.","DOI":"10.1016\/j.mayocp.2018.03.026"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pestronk A, Adams RN, Clawson L, et al. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 38: 1457-1461, 1988.","DOI":"10.1212\/WNL.38.9.1457"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Jolles S. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. Immunotargets Ther 2: 125-133, 2013.","DOI":"10.2147\/ITT.S31136"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 130: 951-957.e11, 2012.","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bril V, Hadden RDM, Brannagan TH, 3rd, et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst 28: 436-449, 2023.","DOI":"10.1111\/jns.12573"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hadden RDM, Andersen H, Bril V, et al. Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: results from the ADVANCE-CIDP 3 trial. J Peripher Nerv Syst 29: 441-452, 2024.","DOI":"10.1111\/jns.12672"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Al-Zuhairy A, Jakobsen J, Andersen H, Sindrup SH, Markvardsen LK. Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy. Eur J Neurol 26: 1289-e82, 2019.","DOI":"10.1111\/ene.13978"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Al-Zuhairy A, Sindrup SH, Jakobsen J. Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy. J Neurol Sci 427: 117495, 2021.","DOI":"10.1016\/j.jns.2021.117495"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Herraets IJT, Bakers JNE, van Eijk RPA, Goedee HS, van der Pol WL, van den Berg LH. Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. J Neurol 266: 2734-2742, 2019.","DOI":"10.1007\/s00415-019-09475-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144, 2008.","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kuwabara S, Mori M, Misawa S, et al. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88: 832-838, 2017.","DOI":"10.1136\/jnnp-2017-316427"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kuwabara S, Oh A, Arakawa M, Kikutani M, Okamatsu N, Sobue G. Maintenance intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy: 18-month post-marketing surveillance in 103 patients. Intern Med 64: 535-541, 2025.","DOI":"10.2169\/internalmedicine.3661-24"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hahn AF, Beydoun SR, Lawson V, et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 18: 321-330, 2013.","DOI":"10.1111\/jns5.12046"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kuwabara S, Misawa S, Mori M, et al. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: a multi-center, open-label, 52-week phase 3 trial. J Peripher Nerv Syst 23: 115-119, 2018.","DOI":"10.1111\/jns.12268"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Terasaka N, Mizushima T, Niwa Y, Akasaki T, Usui H. Real-world safety and treatment patterns of subcutaneous IgPro20 for chronic inflammatory demyelinating polyneuropathy: post-marketing surveillance in Japan. Clin Exp Neuroimmunol 16: 108-117, 2024.","DOI":"10.1111\/cen3.12816"},{"key":"27","unstructured":"27. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17: 35-46, 2018."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 17: 356-363, 2010.","DOI":"10.1111\/j.1468-1331.2009.02930.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5: 223-233, 1999.","DOI":"10.1177\/135245859900500406"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kleyweg RP, van der Mech\u00e9 FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14: 1103-1109, 1991.","DOI":"10.1002\/mus.880141111"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lewis RA, Cornblath DR, Hartung HP, et al. Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review. J Peripher Nerv Syst 25: 230-237, 2020.","DOI":"10.1111\/jns.12402"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Matsui N. Multifocal motor neuropathy: current review of epidemiology and treatment. Rinsho Shinkeigaku (Clinical Neurology) 52: 920-922, 2012 (in Japanese).","DOI":"10.5692\/clinicalneurol.52.920"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Allen JA, Pasnoor M, Dimachkie MM, et al. Quantifying treatment-related fluctuations in CIDP: results of the GRIPPER study. Neurology 96: e1876-e1886, 2021.","DOI":"10.1212\/WNL.0000000000011703"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev: CD004429, 2005.","DOI":"10.1002\/14651858.CD004429.pub2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Baumann A, Hess CW, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 256: 608-614, 2009.","DOI":"10.1007\/s00415-009-0130-0"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Knowles SP, Printz MA, Kang DW, LaBarre MJ, Tannenbaum RP. Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery. Expert Opin Drug Deliv 18: 1673-1685, 2021.","DOI":"10.1080\/17425247.2021.1981286"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6875-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:10:40Z","timestamp":1787371840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6875-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6875-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"6875-25"}}